Biocon Limited Announces Q2 FY26 Earnings Call and Performance Overview
Biocon Limited announces Q2 FY26 results with revenue growth across Biosimilars, Generics, and CRDMO. Earnings call scheduled for November 12, 2025.
The announcement contains significant financial results, strategic initiatives, and future guidance, which are likely to have a high impact on the company's stock and investor sentiment.
The announcement highlights strong revenue growth, successful product launches, improved profitability, and strategic partnerships, indicating a positive outlook for the company.
* Biocon Limited will conduct Q2 FY26 earnings call on November 12, 2025. * The company's Biosimilars and Generics businesses delivered double-digit Y-o-Y growth. * CRDMO business performance is in line with the plan. * The balance sheet was strengthened by settling structured debt obligations, with full benefit of debt reduction visible from FY27, expecting annual savings of approximately ₹300 crore in interest costs. * Several biosimilars were launched across geographies, including bUstekinumab, bAspart, bBevacizumab, and bAflibercept; bDenosumab launch is expected soon. * US FDA approval and settlement for bDenosumab commercialization in the U.S. was achieved. * A partnership with the Government of California was established to supply affordable Insulin Glargine. * The Group recorded improvements in ESG scores. * Q2 FY26 Revenue from Operations was ₹4,296 crore, up 20% YOY. * Total Revenue was ₹4,389 crore, up 21% YOY. * Core EBITDA was ₹1,218 crore, up 23% YOY. * Net Profit (Reported) was ₹85 crore compared to a loss of ₹16 crore last year. * Biosimilars revenue grew 25% YoY to ₹2,721 crore, with EBITDA margin at 25%. * Generics revenue grew 24% YoY to ₹774 crore. * CRDMO revenue increased 2% YoY to ₹911 crore. * Syngene secured its first global phase III clinical trial from a U.S.-based biotech company and will expand its biologics facility in Bengaluru.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.